The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the all-oral regimen of decitabine/cedazuridine, venetoclax, and gilteritinib for the treatment of older unfit patients with FLT3-mutated acute myeloid leukemia (AML) (NCT05010122). This all-oral regimen has shown promising clinical activity while being convenient and well-tolerated. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Astex/Taiho.
